Multibagger Selection: DeepSeek's picks
DeepSeek picked LQDA, ESTA, INOD, CBLL, MLTX with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | DeepSeek |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | LQDA | — | 85% | — | — |
| 2 | ESTA | — | 78% | — | — |
| 3 | INOD | — | 75% | — | — |
| 4 | CBLL | — | 72% | — | — |
| 5 | MLTX | — | 70% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | +11.20% | +12.10% | 1.35x | 0 |
The model's market view
Small and mid-cap equities with identifiable fundamental inflection points and near-term catalysts offer the strongest multibagger potential in the current environment. The market is rewarding companies that demonstrate revenue acceleration, margin expansion, and a clear path to free cash flow inflection, particularly in healthcare and AI-adjacent services. Biotech names with regulatory catalysts and commercial-stage companies with expanding margins are seeing renewed institutional interest, while names with binary clinical readouts carry higher risk but also higher asymmetry. The selections below reflect a mix of commercial-stage inflection stories and late-stage clinical catalysts, each with verifiable time-bound events within 12 months.
Why each pick
LQDA
Liquidia is a commercial-stage biopharmaceutical company that has undergone a dramatic fundamental transformation. Q2 2026 revenue surged to $171.7 million from $8.8 million a year earlier, driven by YUTREPIA net product sales of $170.4 million. The company reported Q2 2026 EPS of $0.74, significantly beating consensus of $0.70, and has now delivered three consecutive quarters of profitability. Gross margin is 91.8%, reflecting the high-value inhaled treprostinil franchise. In October 2026, Liquidia reached a $380.7 million global settlement with United Therapeutics, resolving all six pending lawsuits and removing a major legal overhang that had capped the stock. Preliminary Q3 2026 YUTREPIA net product sales were $222.7 million, beating Street estimates of $201.5 million, with cash and equivalents of $396.1 million as of September 30, 2026. The company has guided toward a $1 billion revenue path in 2027. Analyst consensus price target is $54.38 (56% upside from current levels), with BTIG upgrading to Buy with a $70 target and H.C. Wainwright raising to $65. The strongest counter-evidence is that the stock has already rallied sharply on the settlement news, and the settlement payment of $380.7 million will consume a significant portion of cash. However, the removal of the legal overhang fundamentally changes the risk profile and allows the company to focus on commercial execution. Invalidation would be a close below $28 on above-average volume, or a significant deceleration in YUTREPIA sales in the Q3 earnings report.
ESTA
Establishment Labs is a commercial-stage medical device company that is executing a strong fundamental inflection. Q2 2026 revenue grew 31.7% year-over-year to $67.5 million, with U.S. revenue growing 140.9%. Gross margin expanded to 70.6% from 68.8% a year earlier, and the company expects to transition to free cash flow positive in the second half of 2026 and remain positive for fiscal 2027. The FDA approved an expanded range of Motiva implant sizes in October 2026, adding 28 additional sizes and broadening the addressable market. The company has guided to 2026 revenue of $266.5-268.5 million, up from prior guidance of $264-266 million, representing 25-26% growth. Management projects 2027 revenue growth of at least 25%. The Motiva U.S. IDE Study for breast reconstruction is another potential catalyst, with the company having submitted to the FDA for approval in primary and revision breast reconstruction. The strongest counter-evidence is the stock's high valuation at 8.3x forward sales and 93x price-to-book, which prices in significant growth. However, the company is at an inflection point from cash-burning to cash-generating, which historically drives significant multiple expansion. Analyst consensus price target is $100.70 (64% upside from current levels), with Canaccord Genuity reiterating Buy with a $105 target and BTIG maintaining Buy with a $103 target. Invalidation would be a close below $50 on above-average volume, or a failure to achieve positive free cash flow in H2 2026.
INOD
Innodata is an AI data engineering company that is experiencing explosive revenue growth. Q2 2026 revenue surged 58% year-over-year to $92.1 million, marking the 12th consecutive quarter of year-over-year growth. Adjusted gross margin expanded to 49% from 43% a year ago and 47% in the prior quarter, now nine percentage points above the company's 40% target. Adjusted EBITDA in Q1 2026 was $25.0 million, beating consensus by 139%. The company raised full-year 2026 revenue growth guidance to approximately 40% or more, up from 35%. A major catalyst is the $51 million contract with an unnamed Big Tech customer, which could generate significant revenue in 2026 and potentially expand. Free cash flow is positive at $61.97 million TTM, and the company has a debt-free balance sheet. Analyst consensus price target is $122.75 (117% upside from current levels), with four analysts covering the stock and a Strong Buy consensus. The strongest counter-evidence is the stock's recent pullback from $124.90 to $53.14, a 57% decline from its 52-week high, which reflects concerns about customer concentration and the sustainability of the growth rate. However, the fundamental inflection remains intact, and the valuation has become more attractive. Invalidation would be a close below $45 on above-average volume, or a significant deceleration in revenue growth in the Q3 report.
CBLL
CeriBell is a commercial-stage medical device company with a differentiated point-of-care EEG platform. Q2 2026 revenue grew 33% year-over-year to $28.1 million, and the company raised full-year 2026 revenue guidance to $114-117 million from $112-116 million, implying 28-31% growth. Gross margin is exceptionally high at 92% (89% excluding a tariff refund), reflecting the software-like economics of the Ceribell System. The company has received multiple FDA clearances in 2026, including for quantitative EEG trending, amplitude-integrated EEG analysis, and a first-of-its-kind continuous monitoring solution for delirium. These clearances expanded the total addressable market to $3.5 billion. The company has $129.3 million in cash and marketable securities with no debt, providing ample runway. Analyst consensus price target is $28.57 (21.7% upside from current levels), with a Strong Buy consensus. The strongest counter-evidence is the stock's valuation at 9.8x forward sales, which prices in significant growth, and the analyst target implying only 9.3% upside from the last close of $26.14 (before the recent move to $27.64). However, the company is at an inflection point with expanding TAM and accelerating account additions. Invalidation would be a close below $23 on above-average volume, or a deceleration in revenue growth below 25% in the Q3 report.
MLTX
MoonLake Immunotherapeutics is a clinical-stage biotech with a highly differentiated pipeline asset, sonelokimab (SLK), a tri-specific IL-17A and IL-17F inhibiting Nanobody. The company has completed the BLA submission for SLK in hidradenitis suppurativa (HS) and expects FDA acceptance, including a decision on Priority Review designation, by the end of November 2026. The HS market represents a multi-billion dollar opportunity, and SLK's clinical data from the VELA-1, VELA-2, and MIRA trials have been positive. The company has $537 million in cash and marketable securities as of June 30, 2026, providing runway to mid-2028. The stock has declined from $23.29 to $10.26, a 56% decline from its 52-week high, creating an attractive entry point for a binary catalyst event. Analyst consensus price target is $28.54 (178% upside from current levels), with 15 analysts covering the stock and a Buy consensus. The strongest counter-evidence is the binary nature of the FDA decision: if Priority Review is not granted or the BLA is not accepted, the stock could decline further. However, the pre-BLA meeting with the FDA was positive, and the company has aligned with the FDA on the submission plan. Invalidation would be a close below $8 on above-average volume, or a negative FDA decision on the BLA acceptance.
Other models on the same run
| Model | Picks |
|---|---|
| Gemini 3 Pro | RCAT, EOSE, SOUN, MGNI, SERV |
| Muse Spark 1.1 | ORIC, VSTM, LAC, SG, ENVX |
| Perplexity | MAZE, ETON, AAPG, TPC, GPOR |
| Grok 4 | INOD, ONDS, LUNR, DAVE, FEIM |
| GPT-6 | AMPX, PRCH, ADTN, OUST, EOSE |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.